Science and Gene Therapy
Academic scientists, industry and SME partners will produce innovative gene delivery technologies, reagents and devices to be translated into a simple and safe gene therapeutic treatment for exudative AMD, funded within the 7th Framework Programme of the EU.
The gene-therapeutic approach of TargetAMD bases on the enhanced Sleeping Beauty transposon system (SB100X) which is safe, feasible and efficient. The consortium of TargetAMD promotes:
- The first clinical trial using the SB100X transposon-based, non-viral, integrating vector in Europe.
- Enhancement of the competitiveness of European science by the development of state-of-the-art transposon-based, non-viral transgene delivery technologies.
- Establishment of a new, safe and feasible standard in gene/cell therapy.
- TargetAMD will be the consortium to communicate the regulatory and ethical issues of this new technology on European and International forums as well as with patient organisations.